Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Payables (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Payables for 7 consecutive years, with $7.2 million as the latest value for Q3 2024.

  • On a quarterly basis, Payables fell 11.72% to $7.2 million in Q3 2024 year-over-year; TTM through Sep 2024 was $7.2 million, a 11.72% decrease, with the full-year FY2023 number at $15.9 million, up 57.02% from a year prior.
  • Payables was $7.2 million for Q3 2024 at Actinium Pharmaceuticals, down from $9.2 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $15.9 million in Q4 2023 to a low of $3.4 million in Q2 2021.
  • A 4-year average of $7.3 million and a median of $7.4 million in 2023 define the central range for Payables.
  • Peak YoY movement for Payables: surged 108.56% in 2022, then fell 11.72% in 2024.
  • Actinium Pharmaceuticals' Payables stood at $5.5 million in 2021, then skyrocketed by 83.02% to $10.1 million in 2022, then soared by 57.02% to $15.9 million in 2023, then tumbled by 54.77% to $7.2 million in 2024.
  • Per Business Quant, the three most recent readings for ATNM's Payables are $7.2 million (Q3 2024), $9.2 million (Q2 2024), and $7.5 million (Q1 2024).